Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021
Executive Summary
The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall segment finally returns to growth following the launch of HIF-PHI inhibitor roxadustat, according to Datamonitor Healthcare's latest forecast.
You may also be interested in...
AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.
Next Up For AstraZeneca: Building Out In Renal Disease
US President Ruud Dobber talked to Scrip about expanding in renal disease, balancing the fast-growing oncology portfolio against other priority disease areas, and the company's anticipated return to growth. The big challenge going into 2019, he said, is external factors. "I'm not able to change the view of the President," he said.
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.